AI-Native Scoping Reviews & Evidence Mapping

PCSK9 base editing is moving from experimental promise toward clinical reality, with single-dose therapies already producing durable LDL-C reductions in both primates and early human studies. The full evidence map reveals which delivery platforms, editing strategies, and safety signals are driving this transition—and where the remaining uncertainties still lie.

Giant cell myocarditis is rare, but the evidence map shows why it should never be treated as a diagnostic afterthought: survival depends on early biopsy, rapid combination immunosuppression, and timely escalation to mechanical support or transplantation. The full review distills 169 references into a practical map of prognosis, arrhythmia risk, cardiac sarcoidosis overlap, relapse surveillance, and the unresolved gaps that still shape real-world management.

Aspiration thrombectomy is not a universal “clot-removal solution”: this evidence map shows where it works best, where it fails to improve outcomes, and why stroke, STEMI, PE, DVT, and peripheral indications must be judged separately. The full read gives a clinically useful cross-territory synthesis of device choice, catheter strategy, thrombus biology, rescue techniques, safety signals, and indication-specific evidence gaps.

EPDs are not simply “filters”: across TAVR, carotid stenting, SVG PCI, renal, peripheral, and structural interventions, they reliably capture or deflect embolic material, but clinical benefit depends sharply on anatomy, procedure, device design, and endpoint choice. This evidence map shows where protection appears meaningful, where routine use remains unproven, and why the future of EPDs is likely selective, anatomy-informed deployment rather than universal application.

Impella is not a simple “more support means better outcome” device: across 194 references and 432 original studies, the evidence shows a constant trade-off between ventricular unloading, survival signals, and complications such as bleeding, hemolysis, thrombocytopenia, vascular injury, and acquired von Willebrand syndrome. The full ☸️SAIMSARA evidence map shows where Impella appears strongest — early AMI-cardiogenic shock support, high-risk PCI, bridge-to-transplant/LVAD pathways, and selected RV failure scenarios — and where the evidence remains fragile, observational, or safety-limited.

Air pollution is not just background exposure — this evidence map shows how PM2.5 and traffic-related pollution repeatedly align with CIMT progression, coronary calcium, plaque phenotype, cardiovascular events, and mechanistic vascular injury. Built from 96 references and 186 original studies, the full map gives a practical view of which vascular endpoints are most consistently affected, which populations appear vulnerable, and where prevention or exposure-reduction research should move next.

Phlegmasia cerulea dolens is a rare but catastrophic venous emergency where delayed recognition can mean shock, venous gangrene, amputation, or death. This SAIMSARA evidence map is worth reading because it separates real treatment signals from case-level noise, mapping anticoagulation, thrombolysis, thrombectomy, stenting, fasciotomy, complications, and high-risk contexts across the full clinical spectrum.